| CTRI Number |
CTRI/2025/10/095535 [Registered on: 01/10/2025] Trial Registered Prospectively |
| Last Modified On: |
30/09/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Other (Specify) [Quasi Experimental Study] |
| Study Design |
Other |
|
Public Title of Study
|
Impact of Nurse-Led Lifestyle Modification on Recovery After Angioplasty in Patients With Complex Heart Disease |
|
Scientific Title of Study
|
Effect of nurse-led lifestyle modification program on short term clinical outcomes in patients with higher SYNTAX score undergoing PCI: A quasi experimental study. |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Vandana Devi |
| Designation |
PG student |
| Affiliation |
AIIMS,Jodhpur |
| Address |
Room No. 108,College of Nursing AIIMS Jodhpur, Industrial area,2nd phase,Basni,Jodhpur, Rajasthan.
Jodhpur RAJASTHAN 342005 India |
| Phone |
7355099230 |
| Fax |
|
| Email |
vandanayadav7355@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Nipin Kalal |
| Designation |
Assistant Professor |
| Affiliation |
AIIMS,Jodhpur |
| Address |
ROOM no. 107,First floor, College Of Nursing
AIIMS, Jodhpur,Industrial area,2nd phase,Basni,Jodhpur, Rajasthan
Jodhpur RAJASTHAN 342005 India |
| Phone |
918955945598 |
| Fax |
|
| Email |
kalalnipin@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Nipin Kalal |
| Designation |
Assistant Professor |
| Affiliation |
AIIMS,Jodhpur |
| Address |
Room no.-107,First floor, College Of Nursing
AIIMS, Jodhpur, Industrial area,2nd phase,Basni,Jodhpur, Rjasthan
Jodhpur RAJASTHAN 342005 India |
| Phone |
918955945598 |
| Fax |
|
| Email |
kalalnipin@gmail.com |
|
|
Source of Monetary or Material Support
|
| All India institute of Medical Science, Jodhpur, marudar hi industrial area second phase, Basni, Jodhpur, Rajasthan 342005, INDIA. |
|
|
Primary Sponsor
|
| Name |
NOT APPLICABLE |
| Address |
N/A |
| Type of Sponsor |
Other [Not applicable] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Vandana Devi |
AIIMS Jodhpur |
Room No. 427, 4TH Floor, AIIMS JODHPUR, Industrial area,2nd Phase,Basni,Jodhpur Rajasthan Jodhpur RAJASTHAN |
07355099230
vandanayadav7355@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethical committee, AIIMS JODHPUR |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: I739||Peripheral vascular disease, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Routine care |
The control group will receive standard routine care by Nurse. |
| Intervention |
The experimental group will receive nurse-led lifestyle modification program |
The experimental group will receive a nurse-led lifestyle modification program in addition to the standard treatment. The duration of intervention will be of 1 month. The intervention will consist of three components. First, individualized counseling sessions will be conducted on the day of discharge for the patients and their family members. Each session will last for about 15–20 minutes and will focus on providing health education regarding coronary artery disease, possible post-PCI complications, and lifestyle modifications such as dietary changes, physical activity, smoking and alcohol cessation, stress management, and medication adherence to prevent further complications. Second, a patient information booklet, developed based on these components, will be distributed to the participants at the time of discharge for their reference and reinforcement. Third, telephonic follow-up and reinforcement will be provided on a weekly basis for one month to ensure compliance with the interventions and to address any queries or difficulties faced by the participants. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
75.00 Year(s) |
| Gender |
Both |
| Details |
Participants included in the study will be those who have undergone percutaneous coronary intervention (PCI) and are willing to participate, are above 18 years of age, can understand either Hindi or English, are accessible via telephone, and have a SYNTAX score of 22 or higher. |
|
| ExclusionCriteria |
| Details |
Patient who needs emergency cardiac surgery post PCI.
Patient who are admitted for MACE and going for PCI.
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
Primary CLINICAL OUTCOMES
PART-1: MACE check list
Myocardial infarction (MI), stroke/cerebrovascular event, hospital readmission, revascularization, cardiovascular death and mortality (all-cause)
PART-2: Novel haematological indices
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), monocyte-to-HDL ratio (MHR), high-sensitivity C-reactive protein (hs-CRP), NT-Pro (BNP), and the triglyceride-glucose (TyG) Index.
|
Every week for 1 month |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
Secondary outcomes
Ejection fraction & blood pressure
|
At baseline & after 1 month. |
|
|
Target Sample Size
|
Total Sample Size="60" Sample Size from India="60"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
24/10/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - All of the individual participant data collected during the trial, after de-identification.
- What additional supporting information will be shared?
Response - Study Protocol Response - Statistical Analysis Plan Response - Clinical Study Report
- Who will be able to view these files?
Response - Researchers who provide a methodologically sound proposal.
- For what types of analyses will this data be available?
Response - Any purpose.
- By what mechanism will data be made available?
Response (Others) -
- For how long will this data be available start date provided 02-07-2026 and end date provided 02-11-2031?
Response - Beginning 3 months and ending 5 years following article publication.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - NIL
|
|
Brief Summary
|
Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, contributing to approximately 17.9 million deaths annually, with nearly 85 percent due to heart attacks and strokes. The burden is particularly high in low and middle income countries due to disparities in healthcare access, lifestyle related risk factors, and socioeconomic conditions. Coronary artery disease (CAD), a major type of CVD, occurs when fatty deposits build up in the coronary arteries, restricting blood flow and increasing the risk of heart attacks. Percutaneous coronary intervention (PCI) is a common minimally invasive procedure used to treat CAD, usually through balloon angioplasty or stent placement, but complications such as restenosis, recurrent myocardial infarction, and need for repeat procedures remain. The SYNTAX score is a widely used tool to assess CAD complexity and guide revascularization strategies.
In India, the prevalence of CVD is rising in both urban and rural areas. Patients with higher SYNTAX scores (22 or above) have more complex CAD and face increased risks of adverse events post PCI, including cardiogenic shock, cardiac arrest, stroke, and restenosis. Hematological indices such as neutrophil to lymphocyte ratio, monocyte to lymphocyte ratio, platelet to lymphocyte ratio, systemic immune inflammation index, and systemic inflammation response index have been identified as cost effective prognostic markers for major adverse cardiac events after PCI. Secondary prevention, including adherence to medical therapy and lifestyle modifications like diet, physical activity, smoking cessation, stress management, and medication adherence, reduces complications and improves outcomes. However, patients often face challenges in sustaining these practices without proper guidance. Nurse led lifestyle modification programs have shown effectiveness in improving adherence and recovery, but there is limited evidence regarding their role in patients with higher SYNTAX scores undergoing PCI.
The present study aims to evaluate the effect of a nurse led lifestyle modification program on short term clinical outcomes in patients with higher SYNTAX scores undergoing PCI. The intervention includes individualized health education on diet, exercise, smoking cessation, stress management, and medication adherence, along with distribution of an educational booklet and weekly telephonic follow ups for one month. Short term clinical outcomes will include the occurrence of major adverse cardiac events, changes in novel hematological indices, and secondary outcomes such as ejection fraction and blood pressure, measured after one month of PCI. A higher SYNTAX score will be defined as 22 or above.
The study objectives are to assess and compare short term clinical outcomes in the experimental and control groups, and to examine associations between selected demographic and clinical variables with short term outcomes. The hypotheses to be tested at the 0.05 level of significance are: (H01) there will be no significant difference in short term clinical outcomes between the experimental and control groups, and (H02) there will be no significant association between selected demographic and clinical variables and short term outcomes in both groups. |